Author
Listed:
- Luciano Josué Loyola Bolognesi
- Marcelo Adrián Estrin
Abstract
Introduction: Ischemic colitis is inflammation of the colon caused by decreased blood flow, being the most frequent form of intestinal ischemia. Symptoms can be mild to severe complications such as intestinal perforation. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), which is commonly used, has been associated with various gastrointestinal complications. Currently, several studies have suggested a possible relationship between diclofenac use and ischemic colitis. Objective: To evaluate the impact of diclofenac use on the incidence and severity of ischemic colitis through a systematic review of the available scientific literature. Materials and Methods: An exhaustive search of databases such as Pudmed and Scielo was performed to identify relevant studies that analyzed the relationship between diclofenac use and ischemic colitis, using the following terms: “Colitis”; “Ischemia”; “Diclofenac”; “Colon”; “Anti-Inflammatory Agents, Non- Steroidal”. Observational studies, clinical trials and case reports were included. Data were extracted and analyzed to assess the incidence and severity of ischemic colitis in patients treated with diclofenac. Results: The articles reviewed indicate a significant relationship between the use of diclofenac and the appearance of ischemic colitis. Bielsa Martín et al. (2006) presented specific cases of acute colitis induced by diclofenac. Gleeson and Davis (2003), together with Sierra Gabarda et al. (2022) found a correlation between the use of NSAIDs and the recent diagnosis of ischemic colitis. The proposed mechanisms involve inhibition of prostaglandin synthesis, which affects intestinal mucosal integrity and blood perfusion Conclusion: This systematic review emphasizes the significant impact of diclofenac on the incidence and severity of ischemic colitis. It is recommended that clinicians cautiously evaluate the need to prescribe diclofenac, considering therapeutic alternatives with less risk and monitoring those patients with risk factors. In addition, further research is needed to confirm a conclusive causal relationship and to develop preventive and therapeutic strategies to help reduce the risks associated with diclofenac use.
Suggested Citation
Handle:
RePEc:dbk:southh:2025v4a124
DOI: 10.56294/shp2025196
Download full text from publisher
To our knowledge, this item is not available for
download. To find whether it is available, there are three
options:
1. Check below whether another version of this item is available online.
2. Check on the provider's
web page
whether it is in fact available.
3. Perform a
for a similarly titled item that would be
available.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:dbk:southh:2025v4a124. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Javier Gonzalez-Argote (email available below). General contact details of provider: https://shp.ageditor.ar/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.